Histological confirmation of a non-clear cell renal carcinoma
Item
1. histologically or cytologically confirmed non-clear cell renal cell carcinoma (papillary, chromophobe, collecting duct, oncocytic subtype, sarcomatoid mainly)
boolean
C0449575 (UMLS CUI [1,1])
C0007134 (UMLS CUI [1,2])
Metastasis
Item
2. subjects with metastatic legion
boolean
C0027627 (UMLS CUI [1])
Age
Item
3. subjects aged 18 years or older
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
4. subjects whose ecog performance status is 0 or 1
boolean
C1520224 (UMLS CUI [1])
Hematological laboratory value
Item
5. subjects who have laboratory value below; hematology
boolean
C0022877 (UMLS CUI [1,1])
C0474523 (UMLS CUI [1,2])
Neutrophil count
Item
neutrophil >= 1.5 x 109/l
boolean
C0200633 (UMLS CUI [1,1])
C0205217 (UMLS CUI [1,2])
Platelet count
Item
platelet >= 75 x 109/l
boolean
C0032181 (UMLS CUI [1,1])
C0205217 (UMLS CUI [1,2])
Hemoglobin
Item
hemoglobin >= 9 g/dl liver function tests
boolean
C0019046 (UMLS CUI [1,1])
C0205217 (UMLS CUI [1,2])
Bilirubin
Item
total bilirubin ≤ 1.5 xuln
boolean
C0201913 (UMLS CUI [1,1])
C0205217 (UMLS CUI [1,2])
AST, ALT levels
Item
ast, alt ≤ 2.5 xuln
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
Alkaline phosphatase
Item
alkaline phosphatase ≤ 2.5 xuln renal function tests
boolean
C0201850 (UMLS CUI [1,1])
C0205217 (UMLS CUI [1,2])
Creatinine clearance
Item
creatinine clearance >= 30 ml/min
boolean
C0373595 (UMLS CUI [1])
Informed consent
Item
6. subjects who understand and provide a written informed consent
boolean
C0021430 (UMLS CUI [1])
Administration of an mtor inhibitor
Item
1. subjects who have been administered an mtor inhibitor
boolean
C2746052 (UMLS CUI [1])
Pregnancy or breastfeeding
Item
2. pregnant or nursing women, and women of childbearing potential must use appropriate contraception for the study period and the result of their pregnancy test performed within 14 days before enrollment must be negative
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Former use of study medication
Item
3. subjects who participated in a clinical study using the study medication within 30 days before randomization
boolean
C2348568 (UMLS CUI [1])
CNS metastasis
Item
4. subjects with clinically uncontrolled central nervous system (cns) metastasis
boolean
C0686377 (UMLS CUI [1])
Life expectancy
Item
5. subjects with life expectancy of less than 3 months
boolean
C0023671 (UMLS CUI [1])
Interstitial pulmonary disease
Item
6. subjects with interstitial pulmonary disease
boolean
C0206062 (UMLS CUI [1])
Prolongation of qtc interval
Item
7. subjects whose qtc interval is prolonged (qtc > 450 msec for male or > 470 msec for female)
boolean
C0151878 (UMLS CUI [1])
Concomitant serious diseases or medical conditions
Item
8. other serious diseases or medical conditions heart disease unstable despite treatment history of myocardial infarction within six months before the study history of serious neurological or psychological disorder including dementia or seizure active peptic ulcer which cannot be controlled by a drug
boolean
C0012634 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0018799 (UMLS CUI [2,1])
C0443343 (UMLS CUI [2,2])
C0027051 (UMLS CUI [3])
C0027765 (UMLS CUI [4,1])
C0205404 (UMLS CUI [4,2])
C0497327 (UMLS CUI [5])
C0036572 (UMLS CUI [6])
C0030920 (UMLS CUI [7])